EMEA-002537-PIP02-19
Submitted by Anonymous (not verified) on 22 October 2026 - 10:55
EMEA-002537-PIP02-19
Human medicines European public assessment report (EPAR): Kygevvi, doxecitine,doxribtimine, Date of authorisation: 26/03/2026, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 22 October 2026 - 10:50
Human medicines European public assessment report (EPAR): Kygevvi, doxecitine,doxribtimine, Date of authorisation: 26/03/2026, Revision: 1, Status: Authorised
Immunogenicity and efficacy of pneumococcal vaccines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 16 November 2026, 09:00 (CET) to 17 November 2026, 17:00 (CET)
Submitted by Anonymous (not verified) on 22 October 2026 - 7:00
Immunogenicity and efficacy of pneumococcal vaccines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 16 November 2026, 09:00 (CET) to 17 November 2026, 17:00 (CET)
PSUSA/00000078/202601
Submitted by Anonymous (not verified) on 21 October 2026 - 16:10
PSUSA/00000078/202601
Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Date of authorisation: 20/10/1995, Revision: 28, Status: Authorised
Submitted by Anonymous (not verified) on 21 October 2026 - 16:00
Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Date of authorisation: 20/10/1995, Revision: 28, Status: Authorised
Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 11, Status: Authorised
Submitted by Anonymous (not verified) on 21 October 2026 - 15:52
Human medicines European public assessment report (EPAR): Vyvgart, efgartigimod alfa, Date of authorisation: 10/08/2022, Revision: 11, Status: Authorised
Human medicines European public assessment report (EPAR): Rayvow, lasmiditan, Date of authorisation: 17/08/2022, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 21 October 2026 - 15:50
Human medicines European public assessment report (EPAR): Rayvow, lasmiditan, Date of authorisation: 17/08/2022, Revision: 7, Status: Authorised
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - September 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2026, 10:00 (CEST) to 23 September 2026, 12:00 (CEST)
Submitted by Anonymous (not verified) on 21 October 2026 - 15:10
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - September 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2026, 10:00 (CEST) to 23 September 2026, 12:00 (CEST)
Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 23 September 2026
Submitted by Anonymous (not verified) on 21 October 2026 - 15:09
Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 23 September 2026
Agenda - HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations
Submitted by Anonymous (not verified) on 21 October 2026 - 15:03
Agenda - HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations